Please ensure Javascript is enabled for purposes of website accessibility

Why Johnson & Johnson Stock Sank Today

By Keith Speights - Oct 18, 2019 at 3:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A recall of its baby powder sparked worries about the healthcare giant's asbestos-related legal battles.

What happened

Shares of Johnson & Johnson (JNJ -1.10%) were sinking by 5.9% as of 3:31 p.m. EDT on Friday after the healthcare giant announced a recall of a single lot of its Johnson's Baby Powder. J&J stated in a press release that the recall was initiated "out of an abundance of caution" based on the results of a U.S. Food and Drug Administration (FDA) test that found "sub-trace levels" (no more than 0.00002%) of asbestos contamination in a bottle of its baby powder.

So what

The recall of one lot of a product might not seem like a big enough issue to cause one of the largest companies in the world to lose over $20 billion in market cap. However, the news spooked investors because it highlighted the risk for Johnson & Johnson as it faces multiple lawsuits related to alleged asbestos contamination of its baby powder products.

Baby powder on a black surface next to a pink plastic bottle

Image source: Getty Images.

J&J stated that it's too early to know if there were actually any problems with the lot in question. The company hinted that there could be other causes for the sub-trace presence of asbestos in the single bottle tested by the FDA, including cross-contamination of the sample.

Previous testing conducted by Johnson & Johnson, as well as testing conducted by the FDA, has not found asbestos contamination in the company's baby powder. J&J said that "thousands of tests over the past 40 years repeatedly confirm that our consumer talc products do not contain asbestos."

Now what

Investing in solid dividend stocks like Johnson & Johnson usually means lower volatility than investing in other stocks. However, J&J's asbestos-related legal battles make today's news about its recall more important than it would otherwise be.

Should J&J's recall lead to the discovery of further problems related to asbestos contamination, the stock could take a further beating. However, there's no reason at this point to think this will happen.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.30 (-1.10%) $-1.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.